drugset

drugset / Trial / NCT04695522

ADR-002K for Patients With Ischemic Cardiomyopathy Who Undergo Coronary Artery Bypass Surgery

NCT04695522 ↗

Phase 1 Unknown 6 enrolled Osaka University Rohto Pharmaceutical Co., Ltd. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Ischemic cardiomyopathy undergoing coronary artery bypass surgery

Timeline

Start: 2019-11-27
Primary completion: 2021-04-30
Completion: 2021-10-31

Publications

Kawamura T, Yoshioka D, Kawamura A, Misumi Y, Taguchi T, Mori D, Saito S, Yamauchi T, Hata H, Miyagawa S. Safety and therapeutic potential of allogeneic adipose-derived stem cell spray transplantation in ischemic cardiomyopathy: a phase I clinical trial. J Transl Med. 2024 Dec 2;22(1):1091. doi: 10.1186/s12967-024-05816-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ADR-002K	Cell therapy	—	Other

Indications

No indication recorded.